Transcripta Bio raised $24 million since its Series A to fund IND-enabling studies and advance multiple neuro-focused programs. The company plans to use proceeds for clinical preparation in autism spectrum disorder and facioscapulohumeral muscular dystrophy, with additional pipeline programs in myotonic dystrophy and Huntington’s disease. The fundraising highlights continued investor attention on neurotherapeutics and IND readiness timelines, as platform and mechanism-driven startups compete to reach clinical milestones across genetically and neurologically defined conditions.